BESREMI treatment for polycythemia vera: real-world data
Treatments studied
Part of Blood & lymphatic clinical trials.
This study looks at real-world data from people with polycythemia vera who are taking BESREMI (ropeginterferon alfa-2b). It aims to learn how well the drug works and what side effects people experience in everyday practice, to help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with polycythemia vera (a blood disorder where your body makes too many red blood cells).
- You have already taken at least one dose of the medication BESREMI (ropeginterferon alfa-2b).
- You have complete medical records available for the study team to review, including blood counts and treatment responses.
- You are receiving care at one of the hospitals or clinics taking part in this study.
- You are willing to sign a consent form to allow your data to be used.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a drug called ropeginterferon alfa-2b works for people with polycythemia vera. It aims to understand the drug's effects and safety when used as a first or later treatment option.
This study is testing a medicine called ropeginterferon alfa-2b for people with polycythemia vera (a blood condition) who do not have a swollen spleen that causes symptoms. It looks at how well the medicine works and how it affects your daily life through simple questionnaires.
This trial tests an experimental pill called bomedemstat for people with polycythemia vera who have not responded well to or could not tolerate hydroxyurea. It aims to see if the drug can help control red blood cell counts with fewer side effects.
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
Hear when a new Polycytemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.